Send a message

Medical information spreads rapidly on social media platforms, but not always accurately. When patients encounter alarming headlines about medications they're taking, they naturally bring those concerns to their GP appointments. This episode tackles three recent women's health topics generating buzz online and clarifies what healthcare professionals need to know.

First, we examine the link between Depo-Provera contraceptive injections and brain tumours. 

We also address the critical interaction between GLP-1 medications (particularly Mounjaro) and hormonal contraception. 

Finally, we explore the evidence behind the new five-year cervical screening interval for HPV-negative samples. 

Useful links;

Depo study - Use of progestogens and the risk of intracranial meningioma: national case-control study | The BMJ

FSRH Statement relating to Depo and meningioma - FSRH CEU Statement: Response to new study by Roland et al (2024) | FSRH

Pfizers response - Medroxyprogesterone_acetate_-_Risk_of_meningioma_and_measures_to_minimise_this_risk_-_to_publish.pdf

FSRH Statement on GLP-1 and oral contraception - CEU-statement-GLP-1-agonists-and-contraception.pdf

FSRH Patient information leaflet - Patient-information-GLP-1-agonists-and-contraception.pdf

UK Government statement for GLP-1s - GLP-1 medicines for weight loss and diabetes: what you need to know - GOV.UK

BMJ Study increased cervical screening intervals - Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data | The BMJ

Eve Appeal 5 year interval info - Cervical screening moving to every five years in England  - The Eve Appeal

UK GOV self sampling study - HPValidate cervical screening self-sampling study publishes final results – UK National Screening Committee